This is how global IT leaders solve the difficulty of measuring AI ROI

Danish multinational pharmaceutical company Novo Nordisk is very interested in bringing new drugs to the market as quickly as possible before their patents expire. “For large blockbuster new drugs, even a one-week delay in launch can result in losses ranging from $10 million to $100 million (approximately KRW 14.9 billion to KRW 149.4 billion),” said Stephanie Bova, head of digital innovation (CDTO) at Novo Nordisk. “This is because the time to sell the product during the patent protection period is significantly reduced.” Generative AI has presented the possibility of dramatically shortening several steps in the new drug development process.